CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-12-23): Bristol-Myers liver cancer drug brivanib fails phase III trial

Drug & Device Development

Bristol-Myers liver cancer drug brivanib fails phase III trial

Last Updated: 2011-12-23 19:30:44 -0400 (Reuters Health)

(Reuters) - Bristol-Myers Squibb Co said on Thursday its liver cancer drug brivanib failed to meet the primary endpoint in a late-stage clinical trial.

Brivanib failed to meet the main goal of improving overall survival versus placebo in liver cancer patients who failed or are intolerant to sorafenib. Sorafenib is used to treat advanced primary liver cancer.

Bristol-Myers said three other trials, to evaluate brivanib in different liver cancer patient groups, will continue as planned.

"We remain committed to the development of brivanib as a potential treatment option for patients with liver cancer, and the ongoing study investigating brivanib 'first-line' is expected to complete in 2012," senior vice president Brian Daniels said in a statement.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.